Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type | MicrobiomeTrials← Back to trialsNCT03728972
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2018-11-09Est. Completion: 2025-06-15
Enrollment target: 19 participants Locations- Stanford University, Stanford, California, United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Hackensack Meridian Health, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
- Md Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Lymphoma (Non-Hodgkin's Lymphoma)
This study is designed to evaluate the efficacy and safety of reduced-intensity radiotherapy for stage I/II low-risk nas…
Shanghai, ChinaEst. completion May 1, 2032
Immune Checkpoint InhibitorChemotherapy EffectEpigenetic DisorderNK/T-cell Lymphoma of Nasal Cavity
This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase…
Changsha, ChinaCompleted Jul 1, 2022